Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
57 hedge funds and large institutions have $8.46M invested in Clearside Biomedical in 2019 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 21 reducing their positions, and 19 closing their positions.
1.53% less ownership
Funds ownership: 2.66% → 1.13% (-1.5%)
17% less funds holding
Funds holding: 69 → 57 (-12)
35% less call options, than puts
Call options by funds: $88K | Put options by funds: $136K
38% less capital invested
Capital invested by funds: $13.7M → $8.46M (-$5.21M)
48% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 21
63% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
+$516K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$148K |
| 3 |
State Street
Boston,
Massachusetts
|
+$97.3K |
| 4 |
PA
Parallel Advisors
San Francisco,
California
|
+$83.3K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$32.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.9M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.27M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$1.2M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$641K |
| 5 |
Renaissance Technologies
New York
|
-$635K |
CLSD Hedge Fund Activity: Q1 2019 in Review
57 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q1 2019, worth a combined $8.46M — down 38% from $13.7M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of CLSD and 7 opened new positions — a net loss of 12 holders — while 21 trimmed existing stakes and 11 added.
The largest buyer was Boothbay Fund Management, opening a new position worth an estimated $516K. The largest seller was Wellington Management Group, cutting an estimated $2.9M.
- 57 institutional investors held Clearside Biomedical (CLSD) as of Q1 2019, down from 69 in Q4 2018.
- Funds reported $8.46M of Clearside Biomedical stock for Q1 2019, down 38% quarter-over-quarter.
- 7 funds opened new Clearside Biomedical positions in Q1 2019 and 19 closed out, a net change of -12 holders.
- The largest Clearside Biomedical buyer in Q1 2019 was Boothbay Fund Management, an estimated $516K added.
- The largest Clearside Biomedical seller in Q1 2019 was Wellington Management Group, an estimated $2.9M sold.
Based on aggregated 13F filings for Q1 2019.